Last reviewed · How we verify
NCT07173348: HYPNEA
Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea
NA trial testing Hypnosis in Cancer (With or Without Metastasis) in 82 participants. Not yet recruiting.
1 October 2027
Quick facts
| Lead sponsor | University Hospital, Geneva |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 82 |
| Start date | 1 October 2025 |
| Primary completion | 1 October 2027 |
| Estimated completion | 1 October 2027 |
| Sites | 2 locations across Switzerland |
Drugs / interventions tested
- Hypnosis
Conditions studied
- Cancer (With or Without Metastasis) — all drugs for Cancer (With or Without Metastasis) →
- COPD III/IV — all drugs for COPD III/IV →
- Interstitial Lung Disease (ILD) — all drugs for Interstitial Lung Disease (ILD) →
- Chronic Heart Failure (CHF) — all drugs for Chronic Heart Failure (CHF) →
Sponsor
University Hospital, Geneva
Who can join
18 and older, any sex, with Cancer (With or Without Metastasis) or COPD III/IV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Persistent dyspnea is a debilitating symptom, that is common and difficult to treat. This symptom is found in many different diseases including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), chronic heart failure (CHF), and metastatic cancer. Dyspnea is associated with many other symptoms, including anxiety, depression, and fatigue and is responsible for a significant reduction in quality of life. To date, only opiates are recommended for the pharmacological treatment of persistent dyspnea. The effectiveness of hypnosis is well known in the treatment of anxiety and delivered to patients suffering from chronic dyspnea for this reason. One randomised controlled study has shown that a single 20-minute mindfulness sessions could significantly reduce general symptom burden and have a significant impact on anxiety and depression in palliative care patients. Furthermore, the intervention had no negative side effects. Our aim is to evaluate the effectiveness of three hypnosis sessions on breathlessness mastery in patients with persistent dyspnea, using as a primary outcome the mastery domain of a validated tool, the Chronic Respiratory Questionnaire (CRQ).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07173348
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hypnosis
Trials testing the same drug.
- NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
- NCT07254299 — Hypnosis to Improve Well-beings of Critically Ill Patients and Prevent Post-intensive Care Syndrome · NA · not yet recruiting
- NCT07386392 — Effect of Hypnosis and Virtual Reality on Anxiety During Treatment for Acute Myeloid Leukemia · NA · not yet recruiting
- NCT07256704 — Hypnosis and Attention in Patients With a Neurological Disease (Stroke, Traumatic Brain Injury and Multiple Sclerosis) · NA · recruiting
- NCT06526585 — Stress Management Program · NA · recruiting
Other recruiting trials for Cancer (With or Without Metastasis)
Currently open trials in the same condition.
- NCT07198971 — Feasibility Study Incorporating Music Therapy to Optimise the Smoking Cessation Process Coordinated by a Tobacco Addicti · NA · recruiting
- NCT07290309 — Survivors Uniting for Remote Guided Exercise · NA · recruiting
Other University Hospital, Geneva trials
Trials by the same sponsor.
- NCT07506356 — Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors · recruiting
- NCT07267624 — EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study) · NA · not yet recruiting
- NCT06710210 — Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventi · NA · not yet recruiting
- NCT07129655 — Cholangitis Definition and Treatment After Kasai Hepatoportoenterostomy for Biliary Atresia: TRACK-BA Study (TRacking Ch · not yet recruiting
- NCT07173127 — The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemos · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07173348 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Geneva
- Last refreshed: 15 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07173348.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing